Haberkorn, Anne
Novartis (Switzerland) · Novartis Institutes for BioMedical Research
2 papers on CoChat
Most cited papers
- Verified
M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth
Cortés-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J. S., Yin, H., Muller, A., Haberkorn, A., Chene, P., Sellers, W. R., et al. (2013) · Proceedings of the National Academy of Sciences
Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer
Cited by 159
- Verified
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics
Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways
Cited by 90
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free